Pregled bibliografske jedinice broj: 400863
Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens
Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens // Helicobacter, 14 (2009), 1; 29-35 doi:10.1111/j.1523-5378.2009.00656.x (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 400863 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens
Autori
Filipec Kanižaj, Tajana ; Katičić, Miroslava ; Škurla, Bruno ; Tičak, Mirjana ; Plečko, Vanda ; Kalenić, Smilja
Izvornik
Helicobacter (1083-4389) 14
(2009), 1;
29-35
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
H. pylori; metronidazole; clarithromycin; eradication therapy
Sažetak
The study compares the eradication success of standard first-line triple therapies of different durations (7, 10, and 14 days). A total of 592 naive Helicobacter pylori -positive patients were randomized to receive pantoprazole, amoxicillin, and clarithromycin or metronidazole for 14 days (PACl14 or PAM14), 10 days (PACl10 or PAM10), or 7 days (PACl7 or PAM7). H. pylori eradication was assessed by histological, microbiological, and rapid urease examination. The intention-to-treat (ITT) and per-protocol (PP) analyses have shown no overall statistically significant differences between the eradication success of PACl and PAM treatment groups (ITT p = .308, PP p = .167). Longer treatment duration has yielded statistically significant increase in eradication success for clarithromycin (ITT p = .004 ; PP p = .004) and metronidazole (ITT p = .010 ; PP p = .034) based regimens. Namely, PACl10, PACl14, and PAM14 protocols resulted in eradication success exceeding 80% in ITT and 90% in PP analysis. Primary resistance to clarithromycin and metronidazole equals 8.2% and 32.9%, respectively. Prolonging the metronidazole-based treatment duration in patients with resistant strains resulted in statistically significant higher eradication success. For all antimicrobial combinations, 14 days protocols have led to a significant increase of H. pylori eradication success when compared to 10 and 7 days, respectively. Prolonging the treatment duration can overcome the negative effect of metronidazole resistance. Only PAM14, PACl10 protocols achieved ITT success >80% and should be recommended as the first line eradication treatment in Croatia.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-0000000-3114 - HELICOBAKTER PYLORI INFEKCIJA - EVOLUCIJA BOLESTI I NOVI TERAPIJSKI POSTUPCI (Katičić, Miroslava, MZOS ) ( CroRIS)
108-1080114-0014 - Molekularna detekcija mikroorganizama: utjecaj na uporabu antimikrobnih lijekova (Plečko, Vanda, MZOS ) ( CroRIS)
108-1080114-0017 - Genotipovi i činitelji virulencije uzročnika bolničkih infekcija (Budimir, Ana, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Vanda Plečko
(autor)
Miroslava Katičić
(autor)
Tajana Filipec Kanižaj
(autor)
Smilja Kalenić
(autor)
Poveznice na cjeloviti tekst rada:
Pristup cjelovitom tekstu rada doi www.ncbi.nlm.nih.gov www3.interscience.wiley.comCitiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE